Baltimore, MDNCT06205836Now EnrollingIRB Ready

Colorectal Cancer Clinical Trial in Baltimore, MD

Access cutting-edge colorectal cancer treatment through this phase 2 clinical trial at a research site in Baltimore. Study-provided care at no cost to qualified participants.

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Quick Self-Assessment

See if you qualify for this Baltimore location

Preparing your pre-screening questions…

Expert Care in Baltimore

Access colorectal cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related colorectal cancer treatment provided free

Apply for This Baltimore Location

Check if you qualify for this colorectal cancer clinical trial in Baltimore, MD

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Baltimore

    Convenient for MD residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Baltimore site if eligible
  4. 4Begin participation

About This Colorectal Cancer Study in Baltimore

The purpose of this study is to evaluate the safety and clinical activity of cemiplimab and the combination of cemiplimab/fianlimab in microsatellite unstable localized or locally advanced colorectal cancer diagnosed in patients age 70 or greater or in patients age 18 or greater considered poor candidates for surgery or unwilling to undergo surgery.

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Who Can Participate

Inclusion Criteria

for Cohort A and B:
Age ≥70 years.
Eastern Cooperative Oncology Group (ECOG) performance status 0 -2
Have histologically proven localized or locally advanced mismatch repair deficient (dMMR) or microsatellite unstable (MSI-H) colorectal cancer.
Must not have received any prior systemic treatment or radiation.
Must be agreeable to endoscopic, and CT surveillance for a total of 24 months.
Patient's acceptance to have a tumor biopsy.
Patients must have adequate organ and marrow function defined by study-specified laboratory tests and procedures.
LVEF assessment with documented LVEF ≥ 45% by either TTE or MUGA (TTE preferred) within 6 months from first study drug administration.
For both Women and Men, must use acceptable form of birth control while on study.
Ability to understand and willingness to sign a written informed consent document. Inclusion Criteria for Cohort C and D:
Age ≥18 years.
Eastern Cooperative Oncology Group (ECOG) performance status 0 -3.
Have histologically proven localized or locally advanced mismatch repair deficient (dMMR) or microsatellite unstable (MSI-H) colorectal cancer.
Patient deemed a poor surgical candidate after evaluation by a surgeon or unwilling to undergo surgery.
Must not have received any prior systemic treatment or radiation.
Must be agreeable to endoscopic, and CT surveillance for a total of 24 months.
Patient's acceptance to have a tumor biopsy.
Patients must have adequate organ and marrow function defined by study-specified laboratory tests and procedures.
For both Women and Men, must use acceptable form of birth control while on study.
Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria

for Cohorts A and B:
Have received an investigational agent or used an investigational device within 28 days of the first dose of study drug.
Have expected to require any other form of systemic or localized antineoplastic therapy while on study.
Have had surgery within 28 days of dosing of investigational agent, excluding minor procedures (dental work, skin biopsy, etc.).
History of prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4, or anti-Lag-3 antibodies for any reason in the 5 years proceeding their colorectal cancer diagnosis.
Currently using any chronic systemic steroids.
Patient has received a live vaccine within 30 days of the first dose of study drug.
History of severe hypersensitivity reaction to any monoclonal antibody.
Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.
Active autoimmune disease.
Any tissue or organ allograft, regardless of need for immunosuppression, including corneal allograft.
Patient has a pulse oximetry of \<92% on room air.
Patient is on supplemental home oxygen.
Has clinically significant heart disease.
Cohort B Only: Troponin T (TnT) or troponin I (TnI) \> 2x institutional ULN at baseline.
Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures.
Unwilling or unable to follow the study schedule for any reason Exclusion for Cohort C and D:
Have received an investigational agent or used an investigational device within 28 days of the first dose of study drug.
Have expected to require any other form of systemic or localized antineoplastic therapy while on study.
Currently using any chronic systemic steroids.
Patient has received a live vaccine within 30 days of the first dose of study drug.
History of severe hypersensitivity reaction to any monoclonal antibody.
Any tissue or organ allograft, regardless of need for immunosuppression, including corneal allograft.
Patient is pregnant or breastfeeding.
Cohort D Only: Troponin T (TnT) or troponin I (TnI) \> 2x institutional ULN at baseline.
Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures.
Participation deemed not in the best interest of the patient.
Unwilling or unable to follow the study schedule for any reason.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Baltimore?

Yes, this clinical trial (NCT06205836) has an active research site in Baltimore, MD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Colorectal Cancer Treatment Options in Baltimore, MD

If you're searching for colorectal cancer treatment options in Baltimore, MD, this clinical trial (NCT06205836) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Baltimore research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced colorectal cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all colorectal cancer clinical trials near you to find additional studies recruiting in your area.

More Colorectal Cancer Trials in Baltimore, MD

See all colorectal cancer clinical trials recruiting in Baltimore — not just this study.

Browse Colorectal Cancer Trials in Baltimore →

Browse More Trials by Condition

Colorectal Cancer TrialsAll Conditions →

Ready to Join in Baltimore?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Baltimore, MD